gastrointestinal stromal tumours
GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B
Over 240 million people worldwide live with chronic hepatitis B
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma
More than 50,000 cases of the blood cancer are diagnosed in Europe each year
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination
GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn
Steatotic liver disease affects approximately 5% of the global population
GSK shares promising phase 3 results for linerixibat in PBC-related itch
Pruritus is experienced by up to 90% of patients with the rare liver disease
GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma
Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year